Drug intelligence / Profile preview

Bifidobacterium reuteri Ab.338 SH

Development stage: Preclinical
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Bifidobacterium reuteri Ab.338 SH is a specific probiotic bacterial strain isolated from traditional yogurt, identified by the GenBank accession number PV961363. It is being researched as a live biotherapeutic for its potential antitumor properties, particularly as an adjuvant therapy to enhance the efficacy of chemotherapy in aggressive brain tumors like glioblastoma multiforme (GBM). In preclinical studies using U-87 MG glioblastoma cells, the strain has demonstrated the ability to potentiate the effects of carboplatin by modulating apoptotic and cell cycle regulatory pathways. Its mechanism of action involves the regulation of Caspase, AKT/PTEN, and P53/P21 signaling axes, which are often dysregulated in resistant tumor cells.

Other names: B. reuteri Ab.338 SH

Targets

CASP (Caspase family)TP53 (Cellular Tumor Antigen p53 R175H)AKT (RAC-alpha serine/threonine-protein kinase)CDKN1A (Cyclin-dependent kinase inhibitor 1A)PTEN (Phosphatase and tensin homolog deleted on chromosome ten)

Beyond the preview

Go deeper on Bifidobacterium reuteri Ab.338 SH.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bifidobacterium reuteri Ab.338 SH.

Explore the full profile